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How much actual nano innovation? 
• There are new products, but not many, and  
quite mundane (compared with the breakthrough 
promises) 
• ‘Waiting games’ occur: 
• Nano-enabled drug delivery (“magic bullets”) is pushed by 
researchers but Big Pharma is not interested (or waits) 
• Organic [semi-conducting polymers] large-area electronics: 
interesting but unclear whether there will be a demand – because it 
is unclear what producers will develop (and the producers wait for 
signals from users) 
• Nano in food packaging: the industry is nervous about consumer 
acceptance 
• To understand waiting games in NEST: Include dual 
dynamics of promises  
Dual Dynamics of Promises 
1. Signalling of an
‘opportunity’
Combination of
techno-scientific
possibilities and
societal gains
2. Promises, with
diffuse stories/scenarios
about possible ‘worlds’
3. Accepted promise = agenda
for further techno-scientific
work
4. Requirements: functions that the new
technology must fulfill to meet the promises
5a) ‘Protected space’
for activities
5b) Activities to meet
the requirements
6. Mini-cycles: detailled opportunities,
promises/stories, requirements and activities
7. Certain technological outcomes and uses
including failures 
and 
disappointments 
Promise-requirement 
cycles
Basic idea:  
Van Lente, Rip 
(early 1990s); 
visualization 
by Geels 
Why do waiting games emerge and continue?  
• Umbrella promises: Too Uncertain for actors to 
      Initiate concrete product requirement cycles 
 
 
 
 
 
      
 
 
 
 
 
 
 
 
 
 
 
Innovator 
User 
Waiting 
game 
Reluctant to invest because there is no clear 
demand 
Cannot articulate demand because 
it is not clear what might be offered 
While there are generic promises “Out there” 
that assume that this demand will be realized. 
Somehow!  
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Organic Large Area Electronics 
• Normative reference captured in slogans like:  
      “Towards Green Electronics in Europe” 
 
• Taken up in SRA and policy documents.  
     + reference to a future demand! A $ 300 billion industry by 2027 
 
• Economic interest: Forecast reports (cf. Nanomarkets & IDTechex) 
  
The numbers make an interesting reading 
“Printed electronics” will exceed $7 billion by 2010 
Disposable electronics will be $40 million by 2010 
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• Normative reference captured in slogans like:  
      “Towards Green Electronics in Europe” 
 
• Taken up in SRA and policy documents.  
     + reference to a future demand! A $ 300 billion industry by 2027 
 
• Economic interest: Forecast reports (cf. Nanomarkets & IDTechex) 
  
The numbers make an interesting reading 
“Printed electronics” will exceed $7 billion by 2010 
Disposable electronics will be $40 million by 2010 
 
• Industry analysts warn that Europe might be loosing the race (see 
IDTechEx, is Europe loosing the race) 
 
• Rhetorically very powerful – suggesting that the region will miss 
junction with huge market potential 
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Up to the point – Cintelliq warns for inflated expectations  
(news article on Cintelliq.com, 2009) 
 
“Setting market expectations ahead of what industry realistically can 
achieve will not accelerate technological development nor quicken the 
adoption rate. Failure to do so will lead to Disappointment, Disillusion 
and difficulty to access investments” 
 
“We believe that at this point in the evolution of the industry it is 
pointless to expend time and effort on estimating the future market 
demand for products that do not yet exist” 
 
Organic Large Area Electronics 
Transition from laboratory to products is inhibited by: 
• Novel and unproven technologies + complete new markets 
 
Strategic uncertainty: Technology/product paths 
 
– OPREA vision paper 2008: 
• Organic large area electronics has grown autonomously 
without coherent strategy: No Articulated Directions and 
implementation strategies 
 
– OEA Roadmap 2008: 
• Not able to identify “Killer Application” nor a “Moor’s Law” 
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Organic Large Area Electronics 
Stakeholder meeting report EU commission 2007 
 
– “End-users do not know enough about possibilities of the technology 
due to high complexity” and suggests to educate end-users. 
 
– End-users are not willing to take risks, So: (Device, equipment, 
materials manufacturers) have to take risks. They suggest more 
funding is required especially for manufacturing and demonstration. 
 
Reaction of Heidelberg (a leading printing press manufacturer) 
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cycles 
 
 
“I can’t see Heidelberg commercially printing electronics or 
developing the equipment for a long while yet and there is no point 
in developing a printing kit or system when there are no existing 
customers ready to buy them…….. We want to avoid speculatively 
developing equipment or printed electronics products until the 
technology and the market are more mature” 
 
Nano-enabled drug delivery system 
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 Targeted drug delivery as a magic bullet 
 “Medical wonders at the nano scale” 
Paul Ehrlichs’ ‘Zauberkugeln’ - early 20thC. 
Nano-enabled drug delivery system 
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• ‘Magic Bullet’ constitutes an Umbrella Promise 
• Nano-sized’ targeted drug delivery carriers & more specific promises 
 
Umbrella promise at work: (ETP Nanomedicine 2005 vision paper) 
• contribute to important challenges: patient acceptability, reduction of 
health care costs, and delivery of (difficult to deliver) novel classes of 
drugs.  
 
 
 
 
 
 
 
 Sahoo et al. 2008Source: Allen & Cullis 
(2004) 
Nano-enabled drug delivery system 
Lack of investments 
• Reluctance of large pharma companies towards nano-drug delivery. 
indicated in a review of tech & commercial developments (Couvreur 
and Vauthier, 2006) 
 
 
 
 
 
Lack of articulated demand 
• Indicated by difficulty to involve pharma companies in R&D  
projects or broad stakeholder fora such as the ETP Nanomedicine. 
• MediTrans (EU funded consortium) argues: Lack of involvement of pharma 
companies will impede introduction of nanotechnology in clinics. 
Umbrella 
Promise 
 
 
 
Absence of 
promise 
requirement 
cycles 
 
 
“Today, most developments are carried on by small entrepreneurial 
firms including many spin-ups that cannot support themselves as yet 
on current revenues, whereas big pharmaceutical companies seem 
still awaiting for more successes.” 
• Despite differences between sectors, there is a general pattern, coupled with dual 
dynamics promise.  
For NEST this is structural: it lives on promises. Thus, vulnerable for waiting games. 
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Waiting games - a structural challenge for NEST 
Other explanations for the waiting games 
• Drug Delivery: Intersection of two value chains 
• Carrier development and production &  Drug development and use in treatments 
• Big Pharma waits for innovative startups and Innovative startups wait for investors 
(including big pharma) 
 
Regulatory issues may reinforce waiting games 
• Uncertainties about standards and methodologies for assessments of new nano 
enabled technologies 
  
• Organic electronics: Intersection between many value chains 
• Material suppliers + printer manufacturers are serious  
• Device and system producers are reluctant- No demand articulated 
• So no way to choose among different product development options 
 
Two issues reinforce the waiting game situation: 
• There is also huge technological uncertainty: Existence of reverse sailent 
• Anticipation on changing business models  
 
 
 
In conclusion 
• Other explanations for waiting games derive their force from the 
existence of a diffuse promise. 
• So, waiting games are predicated on the existence of a diffuse 
promise about the potential of a technology which circulates in 
relevant sectors 
 
The absence of promise requirement cycles in dual dynamics of 
promises has the net effect: 
 
• Promises may remain on the radar of the various actors, even 
when little (successful) developments take place. 
How to break through waiting games? 
• In a waiting game situation: No strong initiatives! 
 
The question is what initiatives can breakthrough such difficult situation? 
And more importantly what might happen then? 
 
Our contribution in CTA-workshops: 
• Socio-technical scenarios:  actors try-out different possibilities.  
 
Added value to Roadmaps and actors own analysis: 
• Reduce uncertainty to show initiatives to break through 
• Then, add complexity (non-linear effects, shifts and repercussions) 
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Scenario 2: 
Platform voor een 
‘enabling technologie’
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Scenario 3: 
Alliantie voor targeted
geneesmiddelen
